{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:25:28Z","timestamp":1793827528157,"version":"4.6.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013920","name":"VHL Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016916","name":"Royal Marsden Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.eururo.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:57:45Z","timestamp":1782446265000},"page":"461-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Primary Tumour: Rethinking Biomarker Strategies in Recurrent Renal Cell Carcinoma"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3602-0770","authenticated-orcid":false,"given":"Zayd","family":"Tippu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samra","family":"Turajli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.06.003_b0005","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.003_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115569","article-title":"Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: insights from a European Delphi study","volume":"225","author":"Gr\u00fcnwald","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2026.06.003_b0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA418","article-title":"Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): the randomized phase 3 LITESPARK-022 study","volume":"44","author":"Choueiri","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.003_b0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2026.06.003_b0025","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/2159-8290.CD-24-0499","article-title":"Tracking nongenetic evolution from primary to metastatic ccRCC: TRACERx renal","volume":"15","author":"Fern\u00e1ndez-Sanrom\u00e1n","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2026.06.003_b0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.06.003_b0035","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","article-title":"Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma","volume":"39","author":"Au","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2026.06.003_bib96","first-page":"456","article-title":"Comprehensiev Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-Risk Localized Renal Cell Carcinoma","volume":"90","author":"Xu","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.003_b0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA Class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"issue":"Suppl. 2","key":"10.1016\/j.eururo.2026.06.003_b0045","doi-asserted-by":"crossref","first-page":"S1298","DOI":"10.1016\/j.annonc.2025.08.3207","article-title":"2591O Efficacy of cabozantinib and nivolumab in a cluster 1\/2 metastatic clear cell renal cell carcinoma: results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker","volume":"36","author":"Haake","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.003_b0050","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.06.003_b0055","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176230","article-title":"Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma","volume":"134","author":"Gulati","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2026.06.003_b0060","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41586-026-10428-4","article-title":"Evolutionary characterization of lung cancer metastasis","volume":"653","author":"Hessey","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2026.06.003_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107550","article-title":"Representative sequencing: unbiased sampling of solid tumor tissue","volume":"31","author":"Litchfield","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.eururo.2026.06.003_b0070","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","article-title":"Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes","volume":"26","author":"Nuzzo","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.06.003_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004803","article-title":"Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood","volume":"10","author":"Carlisle","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eururo.2026.06.003_b0080","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.annonc.2025.08.007","article-title":"Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma","volume":"36","author":"Rini","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.003_b0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2025.01.007","article-title":"A call for a neoadjuvant kidney cancer consortium: lessons learned from other cancer types","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.003_b0090","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/2159-8290.CD-25-0099","article-title":"MANIFEST: multiomic platform for cancer immunotherapy","volume":"15","author":"Lim","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2026.06.003_b0095","doi-asserted-by":"crossref","unstructured":"Zhang W, Brown EL, Usmani A, et al. Non-invasive profiling of the tumour microenvironment with spatial ecotypes. Nature. In press. https:\/\/doi.org\/10.1038\/s41586-026-10452-4.","DOI":"10.1038\/s41586-026-10452-4"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:43:58Z","timestamp":1793825038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826022177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0302283826022177"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.06.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the Primary Tumour: Rethinking Biomarker Strategies in Recurrent Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}